Effect of intraoperative HES 6% 130/0.4 on the need for blood transfusion after major oncologic surgery: A propensity-matched analysis

Clinics

Volumn 68, Issue 4, 2013, Pages 501-509

  Zampieri, Fernando Godinho ^a,b,c   Ranzani, Otavio T ^b   Morato, Priscila Fernanda ^a   Campos, Pedro Paulo ^a   Caruso, Pedro ^a,b  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL ALEMÃO OSWALDO CRUZ   (Brazil)

Author keywords

Adverse events; Blood transfusion; Cancer; Surgery; Surgical blood loss; Tetrastarch

Indexed keywords

HETASTARCH DERIVATIVE; PLASMA SUBSTITUTE;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD TRANSFUSION; BRAZIL; DRUG EFFECT; FEMALE; HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; PROPENSITY SCORE; RETROSPECTIVE STUDY; TIME; UTILIZATION REVIEW;

ADULT; AGED; BLOOD COAGULATION; BLOOD TRANSFUSION; BRAZIL; FEMALE; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; PLASMA SUBSTITUTES; PROPENSITY SCORE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84878148635     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(04)11     Document Type: Article

References (43)

1. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products-different effects. Anesthesiology. 2009;111(1):187-202, http://dx.doi.org/10.1097/ALN.0b013e3181a7ec82.
2. Singer M. Management of fluid balance: a European perspective. Curr Opin Anaesthesiol. 2012;25(1):96-101, http://dx.doi.org/10.1097/ACO.0b013e32834e8150.
3. Corcoran T, Emma Joy Rhodes J, Clarke S, Myles PS, Ho KM. Perioperative fluid management strategies in major surgery: a stratified meta-analysis. Anesth Analg. 2012;114(3):640-651, http://dx.doi.org/10.1213/ANE.0b013e318240d6eb.
4. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S, et al. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesth Analg. 2012;114(1):159-169, http://dx.doi.org/10.1213/ANE.0b013e318236b4d6.
5. Schortgen F, Deye N, Brochard L, Group CS. Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med. 2004;30(12):2222-2229, http://dx.doi.org/10.1007/s00134-004-2415-1.
6. Miletin MS, Stewart TE, Norton PG. Influences on physicians' choices of intravenous colloids. Intensive Care Med. 2002;28(7):917-924, http://dx.doi.org/10.1007/s00134-002-1337-z.
7. Sossdorf M, Marx S, Schaarschmidt B, Otto GP, Claus RA, Reinhart K, et al. HES 130/0.4 impairs haemostasis and stimulates pro-inflammatory blood platelet function. Crit Care. 2009;13(6):R208, http://dx.doi.org/10.1186/cc8223.
8. Kozek-Langenecker SA. Effects of hydroxyethyl starch solutions on hemostasis. Anesthesiology. 2005;103(3):654-660, http://dx.doi.org/10.1097/00000542-200509000-00031.
9. de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med. 2001;29(6):1261-1267, http://dx.doi.org/10.1097/00003246-200106000-00038.
10. Franz A, Braunlich P, Gamsjager T, Felfernig M, Gustorff B, Kozek-Langenecker SA. The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg. 2001;92(6):1402-1427, http://dx.doi.org/10.1097/00000539-200106000-00008.
11. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg. 2001;92(4):855-862, http://dx.doi.org/10.1097/00000539-200104000-00011.
12. Kozek-Langenecker SA, Jungheinrich C, Sauermann W, Van der Linden P. The effects of hydroxyethyl starch 130/0.4 (6%) on blood loss and use of blood products in major surgery: a pooled analysis of randomized clinical trials. Anesth Analg. 2008;107(2):382-390, http://dx.doi.org/10.1213/ane.0b013e31817e6eac.
13. Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg. 2011;112(3):635-645, http://dx.doi.org/10.1213/ANE.0b013e31820ad607.
14. Schramko A, Suojaranta-Ylinen R, Kuitunen A, Raivio P, Kukkonen S, Niemi T. Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Br J Anaesth. 2010;104(6):691-697.
15. Hartog CS, Reuter D, Loesche W, Hofmann M, Reinhart K. Influence of hydroxyethyl starch (HES) 130/0.4 on hemostasis as measured by viscoelastic device analysis: a systematic review. Intensive Care Med. 2011;37(11):1725-1737, http://dx.doi.org/10.1007/s00134-011-2385-z.
16. Amar D, Grant FM, Zhang H, Boland PJ, Leung DH, Healey JA. Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery. Anesthesiology. 2003;98(2):337-342, http://dx.doi.org/10.1097/00000542-200302000-00011.
17. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med. 2003;24(4):607-622, http://dx.doi.org/10.1016/S0272-5231(03)00100-X.
18. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149-1156.
19. Gayat E, Pirracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R. Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med. 2010;36(12):1993-2003, http://dx.doi.org/10.1007/s00134-010-1991-5.
20. D'Agostino RB,. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281, http://dx.doi.org/10.1002/(SICI)1097-0258(19981015)17:19,2265::AID-SIM918.3.0.CO;2-B.
21. Hahn RG. Volume kinetics for infusion fluids. Anesthesiology. 2010;113(2):470-481, http://dx.doi.org/10.1097/ALN.0b013e3181dcd88f.
22. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424, http://dx.doi.org/10.1080/00273171.2011.568786.
23. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Instrumental variable analysis of secondary pharmacoepidemiologic data. Epidemiology. 2006;17(4):373-374, http://dx.doi.org/10.1097/01.ede.0000222026.42077.ee.
24. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367(2):124-134.
25. Bellmann R, Feistritzer C, Wiedermann CJ. Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies. Clin Pharmacokinet. 2012;51(4):225-236, http://dx.doi.org/10.2165/11594700-000000000-00000.
26. Abosaif NY, Tolba YA, Heap M, Russell J, El Nahas AM. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis. 2005;46(6):1038-1048, http://dx.doi.org/10.1053/j.ajkd.2005.08.033.
27. Prowle JR, Liu YL, Licari E, Bagshaw SM, Egi M, Haase M, et al. Oliguria as predictive biomarker of acute kidney injury in critically ill patients. Crit Care. 2011;15(4):R172, http://dx.doi.org/10.1186/cc10318.
28. Verheij J, van Lingen A, Beishuizen A, Christiaans HM, de Jong JR, Girbes AR, et al. Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery. Intensive Care Med. 2006;32(7):1030-1038, http://dx.doi.org/10.1007/s00134-006-0195-5.
29. Trof RJ, Sukul SP, Twisk JW, Girbes AR, Groeneveld AB. Greater cardiac response of colloid than saline fluid loading in septic and non-septic critically ill patients with clinical hypovolaemia. Intensive Care Med. 2010;36(4):697-701, http://dx.doi.org/10.1007/s00134-010-1776-x.
30. James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth. 2011;107(5):693-702.
31. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethyl-starch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care. 2012 24;16(3):R94.
32. Lobo SM, Ronchi LS, Oliveira NE, Brandao PG, Froes A, Cunrath GS, et al. Restrictive strategy of intraoperative fluid maintenance during optimization of oxygen delivery decreases major complications after high-risk surgery. Crit Care. 2011;15(5):R226, http://dx.doi.org/10.1186/cc10466.
33. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2011(3):CD000567.
34. Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An overview of coagulation disorders in cancer patients. Surg Oncol. 2010;19(1):e33-e46, http://dx.doi.org/10.1016/j.suronc.2009.03.008.
35. Perisanidis C, Dettke M, Papadogeorgakis N, Schoppmann A, Mittlbock M, Kyzas PA, et al. Transfusion of allogenic leukocyte-depleted packed red blood cells is associated with postoperative morbidity in patients undergoing oral and oropharyngeal cancer surgery. Oral Oncol. 2012;48(4):372-378, http://dx.doi.org/10.1016/j.oraloncology.2011.11.020.
36. Komatsu Y, Orita H, Sakurada M, Maekawa H, Hoppo T, Sato K. Intraoperative blood transfusion contributes to decreased long-term survival of patients with esophageal cancer. World J Surg. 2012;36(4):844-850.
37. Ng T, Ryder BA, Chern H, Sellke FW, Machan JT, Harrington DT, et al. Leukocyte-depleted blood transfusion is associated with decreased survival in resected early-stage lung cancer. J Thorac Cardiovasc Surg. 2012;143(4):815-819, http://dx.doi.org/10.1016/j.jtcvs.2011.12.031.
38. Rzyman W, Dziadziuszko R, Skokowski J, Wilimski R, Raiter A, Szymanowska A, et al. The influence of blood transfusion on survival in operated non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2003;126(3):755-760, http://dx.doi.org/10.1016/S0022-5223(03)00217-4.
39. Hayden SJ, Albert TJ, Watkins TR, Swenson ER. Anemia in Critical Illness: Insights into Etiology, Consequences and Management. Am J Respir Crit Care Med. 2012;185(10):1049-1057, http://dx.doi.org/10.1164/rccm.201110-1915CI.
40. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358(2):125-139.
41. Dubniks M, Persson J, Grande PO. Plasma volume expansion of 5% albumin, 4% gelatin, 6% HES 130/0.4, and normal saline under increased microvascular permeability in the rat. Intensive Care Med. 2007;33(2):293-299, http://dx.doi.org/10.1007/s00134-006-0454-5.
42. Persson J, Grande PO. Plasma volume expansion and transcapillary fluid exchange in skeletal muscle of albumin, dextran, gelatin, hydroxyethyl starch, and saline after trauma in the cat. Crit Care Med. 2006;34(9):2456-2462, http://dx.doi.org/10.1097/01.CCM.0000233876.87978.AB.
43. Doherty M, Buggy DJ. Intraoperative fluids: how much is too much? Br J Anaesth. 2012;109(1):69-79.